CVE-2021-23890

mcafee epolicy orchestrator

TLP:CLEAR

csirt@kutim:~/threat-intel/cve/CVE-2021-23890

Katalog CVE

CVSS 6.5 · Medium EPSS 0,91%

Kerentanan Exposure of Sensitive Information to an Unauthorized Actor pada mcafee epolicy orchestrator. Skor CVSS 3.1 6.5 (Medium) menurut NVD.

Deskripsi (NVD)

Information leak vulnerability in the Agent Handler of McAfee ePolicy Orchestrator (ePO) prior to 5.10 Update 10 allows an unauthenticated user to download McAfee product packages (specifically McAfee Agent) available in ePO repository and install them on their own machines to have it managed and then in turn get policy details from the ePO server. This can only happen when the ePO Agent Handler is installed in a Demilitarized Zone (DMZ) to service machines not connected to the network through a VPN.

Rincian

Terbit di NVD
26 Maret 2021
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
6.5 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-200: Exposure of Sensitive Information to an Unauthorized Actor
EPSS (30 hari)
0,91% peluang dieksploitasi; lebih tinggi dari 58,8% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
mcafee epolicy orchestrator Semua versi sebelum 5.9.1
mcafee epolicy orchestrator Versi 5.10.0
mcafee epolicy orchestrator Versi 5.10.0 update_1
mcafee epolicy orchestrator Versi 5.10.0 update_2
mcafee epolicy orchestrator Versi 5.10.0 update_3
mcafee epolicy orchestrator Versi 5.10.0 update_4
mcafee epolicy orchestrator Versi 5.10.0 update_5
mcafee epolicy orchestrator Versi 5.10.0 update_6
mcafee epolicy orchestrator Versi 5.10.0 update_7
mcafee epolicy orchestrator Versi 5.10.0 update_8
mcafee epolicy orchestrator Versi 5.10.0 update_9

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.